Advancing IgAN Care: Exploring the Next Wave of Treatments - Episode 16
Prospective Improvements of Existing IgAN Therapies
Panelists discuss how current treatments for IgA nephropathy often fall short in addressing the root cause, specifically abnormal IgA production and deposition, and highlight the consequences of prioritizing symptom management, such as proteinuria reduction, over targeting the disease’s underlying pathology.
In what ways do current treatments fail to adequately address the root cause of IgANIgA nephropathy, which is believed to stem from abnormal IgA production and deposition in the kidneys?
What are the consequences of focusing primarily on symptom management (eg, reducing proteinuria) without targeting the disease’s underlying pathology?
